IBBQ vs IBRN: Grades, Fees and Holdings Compared

Invesco Nasdaq Biotechnology ETF

IBBQANasdaq

iShares Neuroscience and Healthcare ETF

IBRNCNYSE Arca

Overlap

6.6%by weight

Expense ratio

IBBQ −0.28pt a year

IBBQ0.19%IBRN0.47%

Avg volume · 30D

IBBQ 13.7×the volume

IBBQ36.6KIBRN2.68K

3Y return · a year

IBBQ +6.0pt

IBBQ+26.4%IBRN+20.4%

IBBQ vs IBRN Performance

Oct 31, 2025 – Oct 30, 2026

+37.1%IBBQ+11.2%IBRN

Expense ratio: IBBQ 0.19%, better; IBRN 0.47%
Fund size: IBBQ $120M; IBRN $7M
1Y total return: IBBQ +37.1%, better; IBRN +11.2%
Yield (12M): IBBQ 1.08%, better; IBRN 0.96%
Holdings: IBBQ 250; IBRN 71
Avg volume (30D): IBBQ 36.6K sh, better; IBRN 2.68K sh
NAV per share: IBBQ $36.17; IBRN $32.81
52W range

ETF.net Grade

Pillar letters and Scores for IBBQ, IBRN, with each pillar’s weight
Pillar	IBBQ	IBRN
Cost30% weight	A100Higher	B56
Mission25% weight	A84	Not scored
Risk15% weight	A73Higher	D28
Tradability15% weight	C48Higher	D25
Holdings10% weight	B62	B65Higher
Durability5% weight	C42Higher	D31

Rank among Biotech & Genomics funds

How we build Categories ›

Same Category. IBBQ and IBRN are both graded against the same 17 Biotech & Genomics funds, so their Grades compare head to head.

Biotech & Genomics⁠

Category · 17 funds

See all 17 ›

IBBQ ranks 2nd and IBRN 10th of 17 funds in the Biotech & Genomics Category.

Rank 1AXBIState Street SPDR S&P Biotech ETFScore 80
Rank 2AIBBQInvesco Nasdaq Biotechnology ETFScore 77
Rank 3AIBBiShares Biotechnology ETFScore 75
Rank 9CSBIOALPS Medical Breakthroughs ETFScore 44
Rank 10CIBRNiShares Neuroscience and Healthcare ETFScore 43
Rank 11CGNMXCorgi Genomics & Precision Medicine ETFScore 40

Our read on each fund

ETF.net Research

IBBQAInvesco Nasdaq Biotechnology ETF

IBRNCiShares Neuroscience and Healthcare ETF

In short

IBBQ The broad Nasdaq biotech benchmark, bought cheap. IBBQ tracks the whole listed biotech and pharma field, roughly 300 names, for 0.19% a year, well under half the typical fee in its category.

IBRN A healthcare fund with one obsession: the brain. IBRN tracks a global index of roughly 70 drugmakers and device companies working on neurological disease, a slice most sector funds bury inside hundreds of names.

Stated mandate

IBBQ The Fund tracks the Nasdaq Biotechnology Index and normally invests at least 90% of its assets in index constituents. The index covers Nasdaq-listed companies classified as biotechnology or pharmaceutical companies.

IBRN The fund seeks to track an index of global companies advancing research and treatment of neurological disorders, providing focused exposure to healthcare innovation related to brain health.

Why people hold it

IBBQ At 0.19% a year, the lowest fee among its closest biotech rivals and less than half the category median.
Holds roughly 300 Nasdaq-listed biotech and pharma companies, so one failed trial or one blockbuster is a slice of the fund, not the whole story.invesco.com
Rules first: normally at least 90% of assets sit in Nasdaq Biotechnology Index constituents. No manager guessing which pipeline pays off.invesco.com
Stands in the top quartile of the biotech and genomics funds we grade, keeping company with far larger rivals like XBI and IBB.

IBRN A rare single-theme cut of healthcare: brain-disease biopharma and medical devices held together, sourced globally rather than US-only.ishares.com
At 0.47%, it undercuts the median expense ratio of its broad healthcare peer group, unusual for a narrow theme fund.
Rules-based, not a stock picker: it follows a published NYSE FactSet neuro index, so the exposure you own is defined in advance.ishares.com

Worth knowing

IBBQ Thinly traded next to the category's giants, so bid-ask spreads can widen. Limit orders matter more here than in a heavily traded fund.
One sector, and a jumpy one: biotech and pharma prices move on trial data and regulatory decisions, a rougher ride than a broad-market fund.invesco.com
Launched in 2021, so a shorter live record and a smaller asset base than the category's long-standing funds.

IBRN Small asset base and thin trading. Spreads can run wider than on the sector's heavyweights, and that cost lands on the buyer.
0.47% is several times what plain broad healthcare index funds like VHT and XLV charge. The theme is what you're paying for.
Roughly 70 names in one research niche, live since 2022. Trial results at a few companies can swing it more than a whole-sector fund.

Full IBBQ profile⁠

Full IBRN profile⁠

IBBQ vs IBRN Holdings

How IBBQ and IBRN differ

Overlap by weight

6.6%

Shared holdings make up 52.7% of IBRN and 6.6% of IBBQ.

Level by level

Holdings26 in both6.6%
Countryby domicile77.5%
Asset classEquity100%

Sector

No Sector split for IBRN.

Country, concentration and asset class

Country by domicile

Country weights in IBBQ and IBRN, widest gap first
Country	More in IBBQMore in IBRN	IBBQ	IBRN
United States	IBBQ +19.4 points	95.2%	75.8%
Belgium	IBRN +4.1 points	0.0%	4.1%
South Korea	IBRN +3.4 points	0.0%	3.4%
Sweden	IBRN +3.2 points	0.0%	3.2%
Denmark	IBRN +2.8 points	0.4%	3.2%
Japan	IBRN +2.3 points	0.0%	2.3%
Australia	IBRN +2.2 points	0.1%	2.3%
United Kingdom	IBBQ +2.0 points	2.0%	0.0%
Other countries (10)	IBRN +3.3 points	2.5%	5.8%

Outside the US: IBRN 75% developed, 25% emerging.

Concentration

Weight in the 10 largest Holdings

IBBQ47.2%
IBRN43.2%

Securities held

IBBQ248
IBRN68

Asset class

IBBQ: Equity
IBRN: Equity

Holdings

Only in IBBQ222
In both26
Only in IBRN42

Only in IBBQ

222 securities, 93.3% of IBBQ by weight

Gilead Sciences Inc8.81%
Amgen Inc8.35%
Vertex Pharmaceuticals Inc7.73%
Moderna Inc5.67%
Regeneron Pharmaceuticals Inc5.27%
Illumina Inc2.79%
Revolution Medicines Inc2.60%
Royalty Pharma PLC1.87%
Roivant Sciences Ltd1.73%
United Therapeutics Corp1.62%
Guardant Health Inc1.58%
Insmed Inc1.55%
Argenx SE1.55%
Incyte Corp1.51%
Alnylam Pharmaceuticals Inc1.48%
Viatris Inc1.40%
Medpace Holdings Inc1.20%
Exelixis Inc1.04%
Ascendis Pharma A/S0.99%
Halozyme Therapeutics Inc0.95%
Bridgebio Pharma Inc0.90%
Tempus AI Inc0.87%
Jazz Pharmaceuticals PLC0.86%
BeOne Medicines Ltd0.85%
Summit Therapeutics Inc0.82%
Twist Bioscience Corp0.73%
BioMarin Pharmaceutical Inc0.71%
BioNTech SE0.66%
Caris Life Sciences Inc0.65%
Kymera Therapeutics Inc0.65%
Madrigal Pharmaceuticals Inc0.63%
10X Genomics Inc0.63%
Krystal Biotech Inc0.61%
Protagonist Therapeutics Inc0.60%
Sanofi SA0.59%
Vaxcyte Inc0.59%
ImmunityBio Inc0.59%
Cytokinetics Inc0.56%
Spyre Therapeutics Inc0.55%
Arrowhead Pharmaceuticals Inc0.55%
Axsome Therapeutics Inc0.48%
Amneal Pharmaceuticals Inc0.47%
Ionis Pharmaceuticals Inc0.47%
GRAIL Inc0.45%
Ligand Pharmaceuticals Inc0.41%
Rhythm Pharmaceuticals Inc0.41%
Oruka Therapeutics Inc0.41%
Kodiak Sciences Inc0.40%
Immunovant Inc0.39%
Mirum Pharmaceuticals Inc0.36%

Only in IBRN

42 securities, 47.7% of IBRN by weight

Argenx SE Adr4.21%
Axogen3.97%
Dianthus Therapeutics3.70%
Sk Biopharmaceuticals Ltd3.52%
H. Lundbeck Class B3.34%
Biohaven3.04%
Neuren Pharmaceuticals2.42%
Bioarctic Class B2.12%
Oncolys Biopharma Inc1.90%
Lb Pharmaceuticals Inc1.61%
Idorsia N Ltd1.57%
Rubicon Research1.33%
Alto Neuroscience1.24%
Integra Lifesciences Holdings1.22%
Dynavox Group1.15%
Medincell SA1.07%
Ceribell1.04%
Apnimed Inc0.99%
Ovid Therapeutics0.71%
Brainsway Adr Representing Ltd0.65%
Bright Minds Biosciences0.65%
Metis Techbio Class H0.55%
Sanbio Ltd0.54%
Neuropace0.53%
Zylox-Tonbridge Medical Tech H0.52%
Capricor Therapeutics0.50%
Benitec Biopharma Inc0.47%
Clearpoint Neuro Inc0.47%
Santhera N AG0.38%
Abeona Therapeutics Inc0.36%
Microport Neurotech Corp0.35%
Newron Pharmaceuticals0.31%
CAMP4 Therapeutics Corp0.23%
Mobia Medical Inc0.22%
Alector0.20%
Nervgen Pharma Corp0.17%
Minerva Neurosciences Inc0.15%
Cognition Therapeutics Inc0.11%
Tonix Pharmaceuticals Holding0.09%
Maplight Therapeutics0.09%
Acumen Pharmaceuticals Inc0.02%
Inr/Usd<0.01%

Weight gaps

All 26 Holdings in both funds, largest gap first.

Holding weights in IBBQ and IBRN, widest gap first
Holding	More in IBBQMore in IBRN	IBBQ	IBRN
Alkermes PLCALKS	IBRN +4.29 points	0.49%	4.78%
Edgewise Therapeutics IncEWTX	IBRN +4.12 points	0.27%	4.39%
PTC Therapeutics IncPTCT	IBRN +3.88 points	0.34%	4.22%
Neurocrine Biosciences IncNBIX	IBRN +3.62 points	0.95%	4.57%
Scholar Rock Holding CorpSRRK	IBRN +3.52 points	0.34%	3.86%
Praxis Precision Medicines IncPRAX	IBRN +3.44 points	0.51%	3.95%
ACADIA Pharmaceuticals IncACAD	IBRN +3.35 points	0.23%	3.58%
Biogen IncBIIB	IBRN +3.23 points	2.35%	5.58%
Dyne Therapeutics IncDYN	IBRN +3.14 points	0.20%	3.34%
Xenon Pharmaceuticals IncXENE	IBRN +2.82 points	0.23%	3.05%
Sarepta Therapeutics IncSRPT	IBRN +2.76 points	0.13%	2.89%
Taysha Gene Therapies IncTSHA	IBRN +1.60 points	0.09%	1.69%
Rapport Therapeutics IncRAPP	IBRN +1.05 points	0.07%	1.12%
Annexon IncANNX	IBRN +0.99 points	0.05%	1.04%
Solid Biosciences IncSLDB	IBRN +0.79 points	0.04%	0.83%
Neurogene IncNGNE	IBRN +0.64 points	0.04%	0.68%
Design Therapeutics IncDSGN	IBRN +0.53 points	0.04%	0.57%
Supernus Pharmaceuticals IncSUPN	IBRN +0.53 points	0.15%	0.68%
Prothena Corp PLCPRTA	IBRN +0.50 points	0.03%	0.53%
Vanda Pharmaceuticals IncVNDA	IBRN +0.33 points	0.02%	0.35%
Kyverna Therapeutics IncKYTX	IBRN +0.33 points	0.02%	0.35%
PepGen IncPEPG	IBRN +0.23 points	0.01%	0.24%
Larimar Therapeutics IncLRMR	IBRN +0.11 points	0.02%	0.13%
Entrada Therapeutics IncTRDA	IBRN +0.11 points	0.01%	0.12%
Anavex Life Sciences CorpAVXL	IBRN +0.09 points	<0.01%	0.10%
Voyager Therapeutics IncVYGR	IBRN +0.08 points	<0.01%	0.09%

All 247 IBBQ holdings⁠All 68 IBRN holdings⁠

How we measure overlap

Each holding counts at its smaller weight in the two funds, summed over the full Holdings. Sector, country and asset class use the same rule on each fund’s split. Cash, FX and derivative lines stay out of the counts. Two bond funds get no overlap figure.

IBBQ vs IBRN Cost

Overpaying IBRN vs IBBQ

$5,466

On $10,000 over 30 years. 7% growth a year before fees, expense ratio only.

IBBQ 0.19%
$3,952
IBRN 0.47%
$9,418

Amount$10,000

Years30 years

Cost over time

IBBQ 0.19%
IBRN 0.47%
Overpaying

Year by year

Year	IBBQ	IBRN	Overpaying
10	$347	$847	$500
20	$1,351	$3,261	$1,910
30	$3,952	$9,418	$5,466

Expense ratio

0.19%IBBQ, cheaper
0.47%IBRN

IBBQ0.19%IBRN0.47%

0.19%0.75%

Middle half of Biotech & Genomics funds
Median 0.47%

IBBQ cheapest of 17 funds

IBRN 8th cheapest of 17 funds

IBBQ vs IBRN Dividends

Last 12 months to Oct 30, 2026

Yield (12M): IBBQ 1.08%, better; IBRN 0.96%
Payout (12M): IBBQ $0.39; IBRN $0.32
Last payment: IBBQ $0.23; IBRN $0.32
Ex-dividend: IBBQ Sep 21, 2026; IBRN Dec 16, 2025
Paid on: IBBQ Sep 25, 2026; IBRN Dec 19, 2025
Frequency: IBBQ Quarterly; IBRN Annual

Distribution history

Per share, 2021 to 2026, same scale for both

IBBQQuarterly · 21 paymentsAll IBBQ payments⁠

IBRNAnnual · 4 paymentsAll IBRN payments⁠

IBBQ vs IBRN Risk

Fall from peak · 5 years

This chart needs five years of history for both funds.

Risk facts

VolatilityStd dev, 3 years: IBBQ 16.8%, betterIBRN 23.6%
Return per unit of riskSharpe ratio, 3 years: IBBQ 1.22, betterIBRN 0.71
Worst fallMax drawdown, 5 years: IBBQ −34.8%IBRN −35.4%since Aug 2022
Market sensitivityBeta, 5 years: IBBQ 0.61IBRN 0.87; Market = 1

Popular comparisons

IBBQAvsXBIA
Invesco Nasdaq Biotechnology ETF · State Street SPDR S&P Biotech ETF
Expense ratio
0.19% · 0.35%
Category
IBRNCvsXBIA
iShares Neuroscience and Healthcare ETF · State Street SPDR S&P Biotech ETF
Expense ratio
0.47% · 0.35%
Category
IBBQAvsIBBA
Invesco Nasdaq Biotechnology ETF · iShares Biotechnology ETF
Expense ratio
0.19% · 0.44%
Category
IBRNCvsIBBA
iShares Neuroscience and Healthcare ETF · iShares Biotechnology ETF
Expense ratio
0.47% · 0.44%
Category
IBBQAvsBBPA
Invesco Nasdaq Biotechnology ETF · Virtus Biotech ETF
Expense ratio
0.19% · 0.34%
Category
IBRNCvsBBPA
iShares Neuroscience and Healthcare ETF · Virtus Biotech ETF
Expense ratio
0.47% · 0.34%
Category